Sökning: onr:"swepub:oai:DiVA.org:uu-360494" >
Overall survival af...
Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014
-
- Stenman, Maria (författare)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Sinclair, G. (författare)
- Karolinska Inst, Dept Neurosurg, S-17176 Stockholm, Sweden;Karolinska Univ Hosp, S-17176 Stockholm, Sweden
-
- Paavola, P. (författare)
- Karolinska Institutet,Uppsala universitet,Experimentell och klinisk onkologi
-
visa fler...
-
- Wersall, P. (författare)
- Karolinska Univ Hosp, S-17176 Stockholm, Sweden;Karolinska Inst, Dept Oncol Pathol, S-17176 Stockholm, Sweden
-
- Harmenberg, U. (författare)
- Karolinska Institutet
-
- Lindskog, Magnus (författare)
- Karolinska Institutet,Uppsala universitet,Experimentell och klinisk onkologi
-
visa färre...
-
(creator_code:org_t)
- ELSEVIER IRELAND LTD, 2018
- 2018
- Engelska.
-
Ingår i: Radiotherapy and Oncology. - : ELSEVIER IRELAND LTD. - 0167-8140 .- 1879-0887. ; 127:3, s. 501-506
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background and purpose: Investigate effects of stereotactic radiotherapy (SRT) or surgical metastasectomy (SM) on overall survival (OS) in metastatic renal cell carcinoma (mRCC) in the era of targeted agents (TA).Material and methods: mRCC patients (n = 117) treated with SRT (n = 57), SM (n = 30) or both modalities sequentially (n = 30) at two oncological centres in Sweden in 2005-2014 were retrospectively included. Median follow-up (mFU) was 63 months.Results: A majority had clear cell histology, 1-3 metastases, and ECOG performance status of 0 or 1. Two thirds had intermediate or poor risk and 44% synchronous metastases. 65% received TA. SRT patients were more likely to have adverse risk profiles. Median OS was 51 months without significant differences between SRT and SM. ECOG 1 vs 0 (HR 2.9; CI 1.6-5.2; p < 0.001), intracranial targets (HR 1.8; CI 1.1-3.2; p = 0.03) and watchful waiting >18 months prior to treatment (HR 0.3; CI 0.2-0.6; p = 0.001) were independently associated with OS. 15% of curatively treated patients (n = 60) were relapse-free with mFU of 87 months.Conclusions: OS after SRT was comparable to SM and longer than expected considering patients with adverse risk profiles were common. Fit patients with non-brain metastases treated after an initial period of watchful waiting had the best prognosis.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Renal cell carcinoma
- Stereotactic radiotherapy
- Gamma knife
- Surgical metastasectomy
- Overall survival
- Prognostic factors
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas